Literature DB >> 3756065

Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man.

A Lelo, D J Birkett, R A Robson, J O Miners.   

Abstract

The pharmacokinetics of caffeine (CA), paraxanthine (PX), theobromine (TB) and theophylline (TP) were studied in six healthy male volunteers after oral administration of each compound on separate occasions. The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively). The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively). The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively). The volume of distribution at steady state of TP (0.44 l kg-1) was lower than that of the other methylxanthines (0.63-0.72 l kg-1). The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756065      PMCID: PMC1401099          DOI: 10.1111/j.1365-2125.1986.tb05246.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Comparison of caffeine metabolism in three nonsmoking populations after oral administration of radiolabeled caffeine.

Authors:  M M Callahan; R S Robertson; A R Branfman; M F McComish; D W Yesair
Journal:  Drug Metab Dispos       Date:  1983 May-Jun       Impact factor: 3.922

2.  The absolute bioavailability of caffeine in man.

Authors:  J Blanchard; S J Sawers
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

4.  Caffeine: a model compound for measuring liver function.

Authors:  E Renner; H Wietholtz; P Huguenin; M J Arnaud; R Preisig
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

5.  Human metabolism of [1-methyl-14C]- and [2-14C]caffeine after oral administration.

Authors:  M M Callahan; R S Robertson; M J Arnaud; A R Branfman; M F McComish; D W Yesair
Journal:  Drug Metab Dispos       Date:  1982 Jul-Aug       Impact factor: 3.922

6.  Theobromine kinetics and metabolic disposition.

Authors:  S M Tarka; M J Arnaud; B H Dvorchik; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1983-10       Impact factor: 6.875

7.  Caffeine disposition after oral doses.

Authors:  M Bonati; R Latini; F Galletti; J F Young; G Tognoni; S Garattini
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

8.  Comparative pharmacokinetics of caffeine in young and elderly men.

Authors:  J Blanchard; S J Sawers
Journal:  J Pharmacokinet Biopharm       Date:  1983-04

9.  Disposition of caffeine and its metabolites in man.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

10.  Theobromine metabolism in man.

Authors:  J O Miners; J Attwood; D J Birkett
Journal:  Drug Metab Dispos       Date:  1982 Nov-Dec       Impact factor: 3.922

View more
  37 in total

Review 1.  Genetics of caffeine consumption and responses to caffeine.

Authors:  Amy Yang; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2010-06-09       Impact factor: 4.530

2.  Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.

Authors:  G E Blakey; J A Lockton; J Perrett; P Norwood; M Russell; Z Aherne; J Plume
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

3.  Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism.

Authors:  S Gates; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

Review 4.  Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease.

Authors:  Simonetta Camandola; Natalie Plick; Mark P Mattson
Journal:  Neurochem Res       Date:  2018-02-08       Impact factor: 3.996

5.  Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites.

Authors:  Tian Yu; Sarah C Campbell; Chris Stockmann; Casey Tak; Katherine Schoen; Erin A S Clark; Michael W Varner; Michael G Spigarelli; Catherine M T Sherwin
Journal:  J Clin Pharmacol       Date:  2015-12-22       Impact factor: 3.126

6.  Psychopharmacology of theobromine in healthy volunteers.

Authors:  Matthew J Baggott; Emma Childs; Amy B Hart; Eveline de Bruin; Abraham A Palmer; Joy E Wilkinson; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2013-02-19       Impact factor: 4.530

7.  The effect of black tea and caffeine on regional cerebral blood flow measured with arterial spin labeling.

Authors:  Rishma Vidyasagar; Arno Greyling; Richard Draijer; Douglas R Corfield; Laura M Parkes
Journal:  J Cereb Blood Flow Metab       Date:  2013-03-13       Impact factor: 6.200

8.  Influence of a CYP1A2 polymorphism on post-exercise heart rate variability in response to caffeine intake: a double-blind, placebo-controlled trial.

Authors:  R M Thomas; H A Algrain; E J Ryan; A Popojas; P Carrigan; A Abdulrahman; A E Carrillo
Journal:  Ir J Med Sci       Date:  2016-07-01       Impact factor: 1.568

9.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04

10.  Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations.

Authors:  D Ullrich; D Compagnone; B Münch; A Brandes; H Hille; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.